TiGenix Business and Financial Update for the First Half 2016

by TIGENIX SAU

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today reported its busi...

Read more

Takeda and TiGenix Announce the Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease

by TIGENIX SAU

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Dis...

Read more

TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial

by TIGENIX SAU

These positive data allow for European filing in the first quarter of 2016 and moving forward in the US with the SPA1-approved pivotal study

Read more

USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

by TIGENIX SAU

The patent, entitled “Use of adipose tissue-derived stromal stem cells in treating fistula”, expires in 2030 and provides coverage for the company’s lead development product, Cx601, in the key U...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Una proteína antibacteriana, nueva dian...

by CSIC - Centro Superior de Investigaciones Científicas

Una investigación liderada por el CSIC describe cómo las células ma...

Photos Stream